JP4611745B2 - ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン - Google Patents
ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン Download PDFInfo
- Publication number
- JP4611745B2 JP4611745B2 JP2004553551A JP2004553551A JP4611745B2 JP 4611745 B2 JP4611745 B2 JP 4611745B2 JP 2004553551 A JP2004553551 A JP 2004553551A JP 2004553551 A JP2004553551 A JP 2004553551A JP 4611745 B2 JP4611745 B2 JP 4611745B2
- Authority
- JP
- Japan
- Prior art keywords
- heteroaryl
- aryl
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QWGIRWNRJPYKAJ-UHFFFAOYSA-N Cc(cc(cc1)Nc2ncnc(cc3)c2cc3-c2c[s]c(CN/C(/N)=N\C#N)n2)c1Oc1ccc(C)nc1 Chemical compound Cc(cc(cc1)Nc2ncnc(cc3)c2cc3-c2c[s]c(CN/C(/N)=N\C#N)n2)c1Oc1ccc(C)nc1 QWGIRWNRJPYKAJ-UHFFFAOYSA-N 0.000 description 1
- HAHMFVLXQADNCA-UHFFFAOYSA-N N#C/N=C(\NCC#Cc(cc1)cc2c1ncnc2Nc1ccc2[n](CC(C=CC3)=CC3F)ncc2c1)/N1CCOCC1 Chemical compound N#C/N=C(\NCC#Cc(cc1)cc2c1ncnc2Nc1ccc2[n](CC(C=CC3)=CC3F)ncc2c1)/N1CCOCC1 HAHMFVLXQADNCA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42754402P | 2002-11-20 | 2002-11-20 | |
| PCT/US2003/035670 WO2004046101A2 (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508979A JP2006508979A (ja) | 2006-03-16 |
| JP2006508979A5 JP2006508979A5 (enExample) | 2006-08-03 |
| JP4611745B2 true JP4611745B2 (ja) | 2011-01-12 |
Family
ID=32326558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553551A Expired - Fee Related JP4611745B2 (ja) | 2002-11-20 | 2003-11-10 | ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1567506A4 (enExample) |
| JP (1) | JP4611745B2 (enExample) |
| AU (1) | AU2003291394B2 (enExample) |
| CA (1) | CA2506503A1 (enExample) |
| NZ (1) | NZ540092A (enExample) |
| WO (1) | WO2004046101A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| KR20080014144A (ko) * | 2003-08-18 | 2008-02-13 | 화이자 프로덕츠 인크. | ｅｒｂＢ２ 항암제에 대한 투약 스케쥴 |
| JP2007505101A (ja) * | 2003-09-11 | 2007-03-08 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム | 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用 |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| JP2008513463A (ja) | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリジンキナーゼ阻害剤 |
| WO2006118749A1 (en) | 2005-05-04 | 2006-11-09 | Janssen Pharmaceutica, N.V. | Thia-tetraazaacenaphthylene kinase inhibitors |
| DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
| CL2007003158A1 (es) * | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
| NZ585357A (en) | 2007-10-29 | 2012-02-24 | Natco Pharma Ltd | Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents |
| JP5721709B2 (ja) * | 2009-07-02 | 2015-05-20 | ニューゲン セラピューティクス， インコーポレイテッド | リンを含むキナゾリン化合物および使用方法 |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CN107915751A (zh) | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| WO2015066482A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3402536A4 (en) | 2016-01-13 | 2019-07-03 | Hadasit Medical Research Services And Development Limited | RADIOACTIVELY MARKED ERLOTINIB ANALOGUES AND USES THEREOF |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
| CN108285421A (zh) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | 一种微通道反应器合成拉帕替尼中间体的方法 |
| JP7620629B2 (ja) * | 2019-12-02 | 2025-01-23 | アカデミア シニカ | ＰＤＩＡ４阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのＰＤＩＡ４阻害剤の使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69536015D1 (de) * | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| WO1997030035A1 (en) * | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3053999A (en) | 1998-03-31 | 1999-10-25 | Kyowa Hakko Kogyo Co. Ltd. | Nitrogenous heterocyclic compounds |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| NZ522568A (en) | 2000-06-22 | 2004-12-24 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
-
2003
- 2003-11-10 EP EP03768789A patent/EP1567506A4/en not_active Withdrawn
- 2003-11-10 AU AU2003291394A patent/AU2003291394B2/en not_active Expired - Fee Related
- 2003-11-10 CA CA002506503A patent/CA2506503A1/en not_active Abandoned
- 2003-11-10 JP JP2004553551A patent/JP4611745B2/ja not_active Expired - Fee Related
- 2003-11-10 WO PCT/US2003/035670 patent/WO2004046101A2/en not_active Ceased
- 2003-11-10 NZ NZ540092A patent/NZ540092A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1567506A4 (en) | 2007-06-20 |
| JP2006508979A (ja) | 2006-03-16 |
| AU2003291394B2 (en) | 2009-06-25 |
| EP1567506A2 (en) | 2005-08-31 |
| WO2004046101A3 (en) | 2004-09-16 |
| CA2506503A1 (en) | 2004-06-03 |
| WO2004046101A2 (en) | 2004-06-03 |
| AU2003291394A1 (en) | 2004-06-15 |
| NZ540092A (en) | 2007-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8088766B2 (en) | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | |
| JP2006508979A (ja) | ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン | |
| CA2290918C (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| CN102741256B (zh) | 对于蛋白激酶具有抑制活性的双环杂芳基衍生物 | |
| JP6090801B2 (ja) | キナーゼ阻害剤としてのアミノキナゾリン | |
| ES2477878T3 (es) | Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas | |
| JP2021523159A (ja) | Ｅｒｂｂ受容体阻害剤 | |
| RS20050180A (sr) | Novi derivati benzoimidazola koji su korisni antiproliferativni agensi | |
| SK17102002A3 (sk) | Substituované bicyklické deriváty na liečbu abnormálneho bunkového rastu | |
| HRP20040529A2 (en) | Quinazoline derivatives for the treatment of abnormal cell growth | |
| US20100016307A1 (en) | Novel compounds | |
| CN113773308A (zh) | Rho激酶抑制剂 | |
| CN108503627A (zh) | 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用 | |
| WO2020156283A1 (zh) | 炔基嘧啶或炔基吡啶类化合物、及其组合物与应用 | |
| CN100455579C (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
| WO2021129561A1 (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
| CN110835333B (zh) | 苯并咪唑取代唑类化合物及其用途 | |
| EP1396489A1 (en) | Heteroaromatic bicyclic derivatives useful as anticancer agents | |
| JP2002322178A (ja) | 二環式環基置換された４−アミノ−ピリドピリミジン誘導体 | |
| RU2810215C2 (ru) | Ингибиторы рецепторов erbb | |
| CN118221696A (zh) | 含有n-甲基哌嗪结构的嘧啶杂环类化合物及其制备方法和应用 | |
| JP5100639B2 (ja) | キナーゼ阻害剤としての置換７，８−ジヒドロ−１ｈ−ピリミド［４，５−ｂ］［１，４］ジアゼピン−４−アミン | |
| CN118772111A (zh) | 一种取代的氨基嘧啶类化合物、药物组合物及其用途 | |
| JP2023528927A (ja) | Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤 | |
| KR20050073238A (ko) | 몰폴린기가 치환된 퀴나졸린 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100723 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100819 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101001 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101014 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131022 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4611745 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |